33 results on '"Huot, Philippe"'
Search Results
2. Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia.
- Author
-
Huot P and Hutchison WD
- Subjects
- Female, Humans, Male, Radionuclide Imaging, Dyskinesias diagnostic imaging, Parkinson Disease diagnostic imaging, Putamen diagnostic imaging, Serotonergic Neurons diagnostic imaging
- Published
- 2015
- Full Text
- View/download PDF
3. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
- Author
-
Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, and Brotchie JM
- Subjects
- Animals, Antiparkinson Agents blood, Antiparkinson Agents cerebrospinal fluid, Antiparkinson Agents pharmacokinetics, Brain drug effects, Brain metabolism, Drug Interactions, Dyskinesias blood, Dyskinesias cerebrospinal fluid, Dyskinesias metabolism, Female, Macaca, Male, Motor Activity drug effects, Parkinson Disease blood, Parkinson Disease cerebrospinal fluid, Parkinson Disease metabolism, Pyridines blood, Pyridines cerebrospinal fluid, Pyridines pharmacokinetics, Pyrroles blood, Pyrroles cerebrospinal fluid, Pyrroles pharmacokinetics, Receptors, Dopamine D4 antagonists & inhibitors, Receptors, Dopamine D4 metabolism, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pharmacology, Antiparkinson Agents pharmacology, Dyskinesias drug therapy, Levodopa pharmacology, Parkinson Disease drug therapy, Pyridines pharmacology, Pyrroles pharmacology
- Abstract
L-DOPA-induced dyskinesia remains an unmet challenge in the treatment of Parkinson's disease (PD). Here, we investigate the potential antidyskinetic efficacy of 3-([4-(4-chlorophenyl)piperazin-1-yl]methyl)-1H-pyrrolo[2,3-b]pyridine (L-745,870), a potent and selective dopamine D(4) receptor antagonist with a good toxicology profile and an excellent safety and tolerability record in phase I/II clinical studies, for non-PD indications. Six macaques were rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. After induction of stable and marked dyskinesia, animals were administered acute challenges of L-745,870 in combination with L-DOPA. To guarantee D(4) selectivity at the doses used in the study, we determined the plasma, cerebrospinal fluid, and brain levels of L-745,870. Coadministration of L-745,870 (1 mg/kg) and L-DOPA significantly reduced the severity of dyskinesia, by up to 59%, in comparison with L-DOPA alone (P < 0.01). L-745,870 had no effect on the duration of antiparkinsonian benefit (ON-time) (P > 0.05). However, L-745,870 (1 mg/kg) significantly increased the duration of ON-time without disabling dyskinesia (+204%; P < 0.001) and decreased duration of ON-time with disabling dyskinesia compared with L-DOPA alone (-56%; P < 0.01). Brain levels of L-745,870 (∼600 ng/g) were within the range at which L-745,870 provides selective D(4) receptor antagonism. Plasma levels were comparable with those demonstrated to be well tolerated in human studies. These data suggest that selective D(4) receptor antagonists represent a potential therapeutic approach for L-DOPA-induced dyskinesia. It is noteworthy that L-745,870 has already undergone significant clinical development, has an excellent profile for a therapeutic candidate, and could be advanced rapidly to phase IIa clinical studies for dyskinesia in PD.
- Published
- 2012
- Full Text
- View/download PDF
4. The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset.
- Author
-
Kwan, Cynthia, Frouni, Imane, Bédard, Dominique, Hamadjida, Adjia, Nuara, Stephen G., Gourdon, Jim C., and Huot, Philippe
- Subjects
DYSKINESIAS ,MARMOSETS ,CALLITHRIX jacchus ,PARKINSON'S disease ,BEHAVIOR disorders ,DOPA - Abstract
Nelotanserin is a serotonin 2A and 2C (5‐HT2A/2C) inverse agonist that was previously tested in the clinic for rapid‐eye movement sleep behaviour disorder and psychosis in patients with Parkinson's disease (PD) dementia. Its effect on L‐3,4‐dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia has however not been investigated. As 5‐HT2A antagonism/inverse agonism is a validated approach to alleviate dyskinesia, we undertook the current study to evaluate the anti‐dyskinetic potential of nelotanserin in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmoset. Parkinsonism was induced in six common marmosets (Callithrix jacchus, three females and three males) that were then chronically treated with L‐DOPA to induce dyskinesia. On experimental days, they were administered L‐DOPA in combination with vehicle or nelotanserin (0.1, 0.3 and 1 mg/kg) subcutaneously, in a randomised fashion. Dyskinesia and parkinsonism were rated post hoc by a blinded observer. In comparison to vehicle, the addition of nelotanserin 0.3 and 1 mg/kg to L‐DOPA diminished peak dose dyskinesia by 47% (P < 0.05) and 69% (P < 0.001). Nelotanserin 0.3 and 1 mg/kg also reduced the severity of global dyskinesia, by 40% (P < 0.01) and 55% (P < 0.001), when compared to vehicle. Nelotanserin 0.1 mg/kg did not alleviate peak dose or global dyskinesia severity. Nelotanserin had no impact on the anti‐parkinsonian action of L‐DOPA. Our results highlight that nelotanserin may represent an efficacious anti‐dyskinetic drug and provide incremental evidence of the potential benefit of 5‐HT2A/2C antagonism/inverse agonism for drug‐induced dyskinesia in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
- Author
-
Kang, Woojin, Nuara, Stephen G., Bédard, Dominique, Frouni, Imane, Kwan, Cynthia, Hamadjida, Adjia, Gourdon, Jim C., Gaudette, Fleur, Beaudry, Francis, and Huot, Philippe
- Subjects
MARMOSETS ,PARKINSONIAN disorders ,PARKINSON'S disease ,DOPAMINE receptors ,DYSKINESIAS ,DOPAMINE agonists - Abstract
LY-404,039 is an orthosteric agonist of metabotropic glutamate 2 and 3 receptors (mGluR
2/3 ) that may harbour additional agonist effect at dopamine D2 receptors. LY-404,039 and its pro-drug, LY-2140023, have previously entered clinical trials as treatment options for schizophrenia. They could therefore be repurposed, if proven efficacious, for other conditions, notably Parkinson's disease (PD). We have previously shown that the mGluR2/3 orthosteric agonist LY-354,740 alleviated L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Unlike LY-404,039, LY-354,740 does not stimulate dopamine D2 receptors, suggesting that LY-404,039 may elicit broader therapeutic effects in PD. Here, we sought to investigate the effect of this possible additional dopamine D2 -agonist action of LY-404,039 by assessing its efficacy on dyskinesia, PLBs and parkinsonism in the MPTP-lesioned marmoset. We first determined the pharmacokinetic profile of LY-404,039 in the marmoset, in order to select doses resulting in plasma concentrations known to be well tolerated in the clinic. Marmosets were then injected L-DOPA with either vehicle or LY-404,039 (0.1, 0.3, 1 and 10 mg/kg). The addition of LY-404,039 10 mg/kg to L-DOPA resulted in a significant reduction of global dyskinesia (by 55%, P < 0.01) and PLBs (by 50%, P < 0.05), as well as reduction of global parkinsonism (by 47%, P < 0.05). Our results provide additional support of the efficacy of mGluR2/3 orthosteric stimulation at alleviating dyskinesia, PLBs and parkinsonism. Because LY-404,039 has already been tested in clinical trials, it could be repurposed for indications related to PD. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
- Author
-
Frouni, Imane, Kwan, Cynthia, Bédard, Dominique, Kang, Woojin, Hamadjida, Adjia, Nuara, Stephen G., Gourdon, Jim C., and Huot, Philippe
- Subjects
DYSKINESIAS ,MARMOSETS ,PARKINSONIAN disorders ,PARKINSON'S disease ,DOPA ,ALLOSTERIC regulation - Abstract
Rationale: Positive allosteric modulation of metabotropic glutamate type 4 (mGlu
4 ) receptors is a promising strategy to alleviate parkinsonian disability and L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia. ADX-88178 is a highly selective mGlu4 positive allosteric modulator (PAM) that previously enhanced the anti-parkinsonian action of L-DOPA in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease (PD). Objectives: We sought to explore the effects of ADX-88178 on psychosis-like behaviours (PLBs) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. We also aimed to determine the effect of ADX-88178 on parkinsonism and dyskinesia. Methods: Six MPTP-lesioned marmosets were administered L-DOPA chronically to induce stable PLBs and dyskinesias. They were then administered ADX-88178 (0.01, 0.1 and 1 mg/kg) or vehicle, in combination with L-DOPA/benserazide (15/3.75 mg/kg), both sub-cutaneously, in a randomised fashion. PLBs, parkinsonism and dyskinesia were then measured. Results: ADX-88178 mildly worsened global PLBs at the dose of 1 mg/kg (by 13%, P = 0.020). L-DOPA alone conferred 158 min of on-time, while the duration of on-time was 212 min (34% increase, P = 0.011), after adding ADX-88178 1 mg/kg to L-DOPA. Accordingly, ADX-88178 1 mg/kg reduced global parkinsonian disability, by 38% (P = 0.0096). ADX-88178 1 mg/kg diminished peak dose dyskinesia by 34% (P = 0.015). Minimal effects were provided by lower doses. Conclusions: Whereas these results provide additional evidence of the anti-parkinsonian and anti-dyskinetic effects of mGlu4 positive allosteric modulation as an adjunct to L-DOPA, they also suggest that ADX-88178 may exacerbate dopaminergic psychosis. Further studies are needed to evaluate this possible adverse effect of mGlu4 PAMs on PD psychosis. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
7. Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset.
- Author
-
Nuara, Stephen G, Gourdon, Jim C, Maddaford, Shawn, and Huot, Philippe
- Subjects
GLUTAMATE receptors ,ALLOSTERIC regulation ,DYSKINESIAS ,MARMOSETS ,PARKINSON'S disease - Abstract
Purpose: Antagonising serotonin (5-HT) type 2A receptors (5-HT
2A R) is an effective strategy to alleviate both dyskinesia and psychosis in Parkinson's disease (PD). We have recently shown that activation of metabotropic glutamate 2 receptors (mGluR2 ), via either orthosteric stimulation or positive allosteric modulation, enhances the anti-dyskinetic and anti-psychotic effects of 5-HT2A R antagonism. Here, we investigated if greater therapeutic efficacy would be achieved by combining 5-HT2A R antagonism with concurrent mGluR2 orthosteric stimulation and mGluR2 positive allosteric modulation. Methods: Five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets exhibiting dyskinesia and psychosis-like behaviours (PLBs) were administered l-3,4-dihydroxyphenylalanine (l-DOPA) in combination with vehicle or the 5-HT2A R antagonist EMD-281,014. EMD-281,014 was itself administered alone or with the mGluR2 orthosteric agonist (OA) LY-354,740, the mGluR2 positive allosteric modulator (PAM) LY-487,379 and combination thereof, after which the severity of dyskinesia, PLBs and parkinsonism was rated. Results: EMD-281,014 reduced dyskinesia and PLBs by up to 47% and 40%, respectively (both P < 0.001). The addition of LY-354,740, LY-487,379 and LY-354,740/LY-487,379 decreased dyskinesia by 56%, 65% and 77%, while PLBs were diminished by 55%, 63% and 71% (all P < 0.001). All treatment combinations provided anti-dyskinetic and anti-psychotic benefits significantly greater than those conferred by EMD-281,014 alone (all P < 0.05). The combination of EMD-281,014/LY-354,740/LY-487,379 resulted in anti-dyskinetic and anti-psychotic effects significantly greater than those conferred by EMD-281,014 with either LY-354,740 or LY-487,379 (both P < 0.05). No deleterious effects on l-DOPA anti-parkinsonian action were observed. Conclusion: Our results suggest that combining 5-HT2A R antagonism with mGluR2 activation results in greater reduction of l-DOPA-induced dyskinesia and PD psychosis. They also indicate that further additive effect can be achieved when a mGluR2 OA and a mGluR2 PAM are combined with a 5-HT2A R antagonist than when a mGluR2 OA or a mGluR2 PAM are added to a 5-HT2A R antagonist. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
- Author
-
Frouni, Imane, Kwan, Cynthia, Nuara, Stephen G., Belliveau, Sébastien, Kang, Woojin, Hamadjida, Adjia, Bédard, Dominique, Gourdon, Jim C., and Huot, Philippe
- Subjects
DYSKINESIAS ,MARMOSETS ,PARKINSON'S disease ,PARKINSONIAN disorders ,ALLOSTERIC regulation - Abstract
Advanced Parkinson's disease (PD) is often complicated by the occurrence of dyskinesia, motor fluctuations and psychosis. To this day, few treatment options are available for each of these phenomena, and they are at times not effective or elicit adverse events, leaving some patients short of therapeutic options. We have recently shown that positive allosteric modulation of metabotropic 2 (mGlu
2 ) receptors with the prototypical positive allosteric modulator (PAM) LY-487,379 is efficacious at alleviating both dyskinesia and psychosis-like behaviours (PLBs), while simultaneously enhancing the anti-parkinsonian action of L-3,4-dihydroxyphenylalanine (L-DOPA), in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Here, we assessed the effects of CBiPES, a mGlu2 PAM derived from LY-487,379, but with improved pharmacokinetic properties. Six MPTP-lesioned marmosets with reproducible dyskinesia and PLBs were administered L-DOPA in combination with vehicle or CBiPES (0.1, 1 and 10 mg/kg), after which their behaviour was rated. CBiPES 10 mg/kg reduced global dyskinesia by 60% (P < 0.0001), while peak dose dyskinesia was reduced by 66% (P < 0.001), compared to L-DOPA/vehicle. CBiPES 10 mg/kg also diminished global PLBs by 56% (P < 0.0001), while peak dose PLBs were reduced by 64% (P < 0.001), compared to L-DOPA/vehicle. Lastly, CBiPES enhanced the anti-parkinsonian action of L-DOPA, by reducing global parkinsonian disability by 43% (P < 0.01), compared to L-DOPA/vehicle. Our results provide further evidence that mGlu2 positive allosteric modulation may be an approach that could be efficacious for the treatment of dyskinesia, psychosis and motor fluctuations in PD. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
- Author
-
Hamadjida, Adjia, Nuara, Stephen G., Kwan, Cynthia, Frouni, Imane, Bédard, Dominique, Gourdon, Jim C., and Huot, Philippe
- Subjects
MONOAMINE oxidase ,DOPA ,MARMOSETS ,PARKINSON'S disease ,DYSKINESIAS - Abstract
Whereas monoamine oxidase (MAO) type B inhibitors are used as adjunct to L-3,4-dihydroxyphenylalanine (L-DOPA) in the treatment of Parkinson's disease (PD), the enzyme MAO type A (MAO-A) also participates in the metabolism of dopamine in the human and primate striatum. Here, we sought to assess the effect of the selective reversible MAO-A inhibitor moclobemide on L-DOPA anti-parkinsonian in the gold standard animal model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate. We also assessed the effect of moclobemide on L-DOPA-induced dyskinesia and psychosis-like behaviours (PLBs). Experiments were performed in six MPTP-lesioned marmosets chronically treated with L-DOPA and exhibiting stable dyskinesia and PLBs upon each administration. In a randomised within-subject design, animals were administered a therapeutic dose of L-DOPA in combination with moclobemide (0.1, 1 and 10 mg/kg) or its vehicle, after which the severity of parkinsonism, dyskinesia, and PLBs was rated by an experienced blinded rater. Moclobemide significantly reduced the global parkinsonian disability (− 36% with 0.1 mg/kg, P < 0.05; − 38% with 1 mg/kg, P < 0.01; − 47% with 10 mg/kg, P < 0.01), when compared with its vehicle. This reduction of parkinsonism was not accompanied by an exacerbation of dyskinesia or PLBs. Reversible MAO-A inhibition with moclobemide appears as an effective way to increase the anti-parkinsonian action of L-DOPA, without negatively affecting dyskinesia or dopaminergic psychosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
- Author
-
Beaudry, Francis and Huot, Philippe
- Subjects
- *
PARKINSON'S disease , *DYSKINESIAS , *MARMOSETS , *CALLITHRIX jacchus , *CLINICAL drug trials , *CLINICAL trials - Abstract
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset has been used extensively to model Parkinson's disease, l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia and, more recently, dopaminergic psychosis. Whereas several experimental drugs have been tested in this primate, many of which subsequently underwent clinical trials, efficacy thresholds in the marmoset that would predict efficacy in the clinic are lacking. Here, we aimed to determine such efficacy end points that would be indicative of likely efficacy in clinical studies. To do so, we used the evidence-based medicine reviews published by the International Parkinson and Movement Disorder Society (IPMDS) to select drugs that were rated as clinically efficacious, likely efficacious or not efficacious for the treatment of parkinsonism, dyskinesia and psychosis. We then reviewed the literature in the MPTP-lesioned marmoset and identified articles reporting the effects of drugs that were included in the IPMDS recommendations, following which we estimated efficacy thresholds in the marmoset that would predict efficacy at the clinical level. We propose that, when drugs are administered as monotherapy, ≥ 50% reduction of global parkinsonism may be necessary to predict the possibility of clinical efficacy. As adjunct to a low dose of l-DOPA, we propose that an additional reduction of global parkinsonism ≥ 25% might predict clinical efficacy. As adjunct to an optimal dose of l-DOPA, we propose that additional anti-parkinsonian benefit ≥ 20%, with global parkinsonism as the end point, might predict clinical efficacy. For the treatment of dyskinesia, we suggest that the predictability threshold be set at ≥ 25% reduction of peak dose dyskinesia, while we believe that this threshold should be > 50% reduction of peak dose psychosis-like behaviours for psychosis-related end points. This article represents the first step in determining what efficacy might be necessary to achieve in pre-clinical studies in the MPTP-lesioned marmoset prior to confidently advancing drugs to clinical trials. We hope that it will help in the drug discovery and development process, notably by avoiding exposing patients to drugs that have little probability of clinical efficacy based upon pre-clinical experiments. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset.
- Author
-
Nuara, Stephen G., Hamadjida, Adjia, Gourdon, Jim C., and Huot, Philippe
- Subjects
MARMOSETS ,PARKINSON'S disease ,ALLOSTERIC regulation ,DOPA ,DYSKINESIAS - Abstract
We have recently shown that activation of metabotropic glutamate 2 (mGlu
2 ) receptors through positive allosteric modulation and orthosteric stimulation is a novel approach to reduce L-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia and dopaminergic psychosis in Parkinson's disease (PD). We have obtained these benefits with the mGlu2 -positive allosteric modulator (PAM) LY-487,379 and the mGlu2/3 orthosteric agonist (OA) LY-354,740 in experiments conducted in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Here, we sought to pharmacologically characterise the anti-dyskinetic and anti-psychotic effects of LY-487,379 and LY-354,740, by assessing whether their benefits would be reversed by the mGlu2/3 orthosteric antagonist LY-341,495. Six MPTP-lesioned marmosets exhibiting stable dyskinesia and psychosis-like behaviours (PLBs) entered the experiments. In the first series of experiments, animals were injected l-DOPA in combination with either vehicle, LY-487,379 (10 mg/kg), LY-341,495 (1 mg/kg) or LY-487,379/LY-341,495. In the second series of experiments, marmosets were injected l-DOPA in combination with either vehicle, LY-354,740 (1 mg/kg), LY-341,495 (1 mg/kg) or LY-354,740/LY-341495. As we previously demonstrated, both LY-487,379 and LY-354,740 alleviated dyskinesia (by 44% and 47%, both P < 0.001) and PLBs (by 44% and 39%, P < 0.01 and P < 0.001) when compared to vehicle treatment. When LY-487,379 and LY-354,740 were administered concurrently with LY-341,495, the anti-dyskinetic and anti-psychotic benefits were abolished. When administered with l-DOPA in the absence of LY-487,379 and LY-354,740, LY-341,495 did not worsen dyskinesia or PLBs and did not hamper l-DOPA anti-parkinsonian action. Our results indicate that the anti-dyskinetic and anti-psychotic effects of mGlu2 -positive allosteric modulation and mGlu2/3 orthosteric stimulation are reversed by mGlu2/3 orthosteric blockade. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset.
- Author
-
Nuara, Stephen G., Hamadjida, Adjia, Kwan, Cynthia, Bédard, Dominique, Frouni, Imane, Gourdon, Jim C., and Huot, Philippe
- Subjects
GLUTAMATE receptors ,ALLOSTERIC regulation ,DYSKINESIAS ,MARMOSETS ,PARKINSON'S disease ,TREATMENT effectiveness - Abstract
In recent studies performed in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson's disease (PD), we have demonstrated that activation of the metabotropic glutamate 2 (mGlu
2 ) receptor with the orthosteric agonist (OA) LY-354,740 and the positive allosteric modulator (PAM) LY-487,379 is effective at alleviating both dyskinesia and psychosis-like behaviours (PLBs) triggered by the administration of l-3,4-dihydroxyphenylalanine (l-DOPA). Because mGlu2 OAs and PAMs bind to different sites on the receptor, we hypothesised that greater reductions of dyskinesia and PLBs would be obtained upon concurrent administration of LY-354,740 and LY-487,379. In experiments performed in six MPTP-lesioned marmosets, we administered LY-354,740 (0.1 mg/kg), LY-487,379 (1 mg/kg), LY-354,740 (0.1 mg/kg) + LY-487,379 (1 mg/kg), or vehicle, in combination with l-DOPA and determined the effect of each treatment on dyskinesia, PLBs, and parkinsonism. When compared to vehicle, LY-354,740 and LY-487,379, administered alone or concurrently, significantly reduced dyskinesia. The combination LY-354,740 + LY-487,379 provided mild additional benefit when compared to LY-487,379 alone, but not compared to LY-354,740. For PLBs, when compared to vehicle treatment, LY-354,740, LY-487,379, and combination thereof all alleviated the abnormal behaviours, but the combination LY-354,740 + LY-487,379 did not provide greater relief than either drug alone. The anti-parkinsonian effect of l-DOPA was not altered by any of the treatments. Our results provide further evidence that mGlu2 activation might be a novel approach to treat l-DOPA-induced dyskinesia and dopaminergic psychosis in PD. However, they do not suggest that greater therapeutic effect would be achieved upon combining an mGlu2 OA and an mGlu2 PAM. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease.
- Author
-
Hamadjida, Adjia, Sid‐Otmane, Lamia, Kwan, Cynthia, Frouni, Imane, Nafade, Vaidehi, Bédard, Dominique, Gagnon, Dave, Wallman, Marie‐Josée, Rouillard, Claude, Parent, André, Parent, Martin, and Huot, Philippe
- Subjects
PARKINSON'S disease ,DYSKINESIAS ,RATS ,DOPA - Abstract
l‐3,4‐Dihydroxyphenylalanine (l‐DOPA) is the most effective treatment for Parkinson's disease (PD), but its use over a long period is marred by motors complications such as dyskinesia. We previously demonstrated that selective metabotropic glutamate 2/3 (mGlu2/3) receptor activation with LY‐354,740 alleviates dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmoset and the 6‐hydroxydopamine (6‐OHDA)‐lesioned rat. Here, we sought to determine the role played by selective mGlu2 activation in the anti‐dyskinetic effect of mGlu2/3 stimulation and have investigated the effect of the highly selective mGlu2 positive allosteric modulator LY‐487,379 at alleviating established, and preventing the development of, l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat. First, dyskinetic 6‐OHDA‐lesioned rats were administered l‐DOPA in combination with LY‐487,379 (0.1, 1 and 10 mg/kg) or vehicle, and the severity of dyskinesia was determined. Second, 6‐OHDA‐lesioned rats were administered LY‐487,379 (0.1 or 1 mg/kg), started concurrently with l‐DOPA, once daily for 22 days, and dyskinesia severity was evaluated weekly for four consecutive weeks. We also assessed the effect of LY‐487,379 on l‐DOPA anti‐parkinsonian effect. We found that acute challenges of LY‐487,379 0.1 mg/kg in combination with l‐DOPA, significantly diminished dyskinesia severity, by ≈54% (p <.01), when compared to vehicle. Moreover, animals treated with l‐DOPA/LY‐487,379 0.1 and 1 mg/kg during the dyskinesia induction phase exhibited milder dyskinesia, by ≈74% and ≈61%, respectively (both p <.01), when compared to l‐DOPA/vehicle. LY‐487,379 did not impair l‐DOPA anti‐parkinsonian activity. These results suggest that mGlu2 activation may be an effective and promising therapeutic strategy to alleviate the severity and prevent the development of dyskinesia. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. 5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.
- Author
-
Kwan, Cynthia, Frouni, Imane, Bédard, Dominique, Nuara, Stephen G., Gourdon, Jim C., Hamadjida, Adjia, and Huot, Philippe
- Subjects
DYSKINESIAS ,PARKINSON'S disease ,MARMOSETS ,PSYCHOSES ,DOPA - Abstract
Virtually every patient affected by Parkinson's disease (PD) eventually requires treatment with L-3,4-dihydroxyphenylalanine (L-DOPA), which leads to complications such as dyskinesia and psychosis. Whereas blockade of serotonin 2A (5-HT
2A ) receptors appears to be an effective way to reduce both dyskinesia and psychosis, whether it has the potential to eliminate the two phenomena remains to be determined. In a previous study, we showed that highly selective 5-HT2A receptor blockade with EMD-281,014, at plasma levels comparable to those achieved in the clinic, reduced dyskinesia and psychosis-like behaviours (PLBs), in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Here, we sought to determine whether further increasing the dose would result in greater therapeutic benefit or if maximal effectiveness was achieved at lower doses. Six MPTP-lesioned marmosets with stable dyskinesia and PLBs were administered EMD-281,014 (0.1, 1 and 10 mg/kg) or vehicle in combination with L-DOPA and the effect on dyskinesia, PLBs and parkinsonism was assessed. Administration of EMD-281,014 (0.1, 1 and 10 mg/kg) in combination with L-DOPA resulted in a significant reduction in the severity of dyskinesia, by up to 63%, 64% and 61% (each P < 0.001), when compared to L-DOPA/vehicle. Similarly, the addition of EMD-281,014 (0.1, 1 and 10 mg/kg) to L-DOPA also significantly decreased the severity of PLBs, by up to 54%, 55% and 53% (each P < 0.001), when compared to L-DOPA/vehicle. Our results suggest that there might be a ceiling to the reduction of dyskinesia and psychosis that can be achieved through antagonism of 5-HT2A receptors. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat.
- Author
-
Frouni, Imane, Kwan, Cynthia, Bédard, Dominique, Belliveau, Sébastien, Bourgeois-Cayer, Élodie, Gaudette, Fleur, Beaudry, Francis, Hamadjida, Adjia, and Huot, Philippe
- Subjects
DYSKINESIAS ,DOPA - Abstract
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective therapy for motor symptoms of Parkinson's disease (PD); however, with repeated administration, as many as 94% of PD patients develop complications such as L-DOPA-induced dyskinesia. We previously demonstrated that EMD-281,014, a highly selective serotonin 2A (5-HT
2A ) receptor antagonist, reduces the severity of dyskinesia in the parkinsonian marmoset, without interfering with L-DOPA anti-parkinsonian benefit. Here, we assessed the effects of EMD-281,014 on L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat. We first determined the pharmacokinetic profile of EMD-281,014, to administer doses leading to clinically relevant plasma levels in the behavioural experiments. Dyskinetic 6-OHDA-lesioned rats were then administered EMD-281,014 (0.01, 0.03 and 0.1 mg/kg) or vehicle in combination with L-DOPA and AIMs severity was evaluated. We also assessed the effect of EMD-281,014 on L-DOPA anti-parkinsonian action with the cylinder test. We found that the addition of EMD-281,014 (0.01, 0.03 and 0.1 mg/kg) to L-DOPA did not reduce AIMs severity (P > 0.05), when compared to vehicle. EMD-281,014 did not compromise L-DOPA anti-parkinsonian action. Our results suggest that the highly selective 5-HT2A receptor antagonist EMD-281,014 is well-tolerated by parkinsonian rats, but does not attenuate L-DOPA-induced AIMs. Our results highlight differences between rodent and primate models of PD when it comes to determining the anti-dyskinetic action of 5-HT2A receptor antagonists. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease.
- Author
-
Hamadjida, Adjia, Nuara, Stephen G., Gourdon, Jim C., and Huot, Philippe
- Subjects
TRAZODONE ,DYSKINESIAS ,DRUG therapy for psychoses ,PARKINSON'S disease patients ,DRUG efficacy ,MARMOSETS as laboratory animals ,THERAPEUTICS - Abstract
Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson’s disease (PD). Here, we investigated the anti-dyskinetic and anti-psychotic effects of trazodone in the parkinsonian non-human primate. 6 common marmosets were rendered parkinsonian by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Following repeated administration of L-DOPA to induce stable dyskinesia and psychosis-like behaviours (PLBs), trazodone (0.1, 1 and 10 mg/kg) or vehicle was administered in combination with L-DOPA and its effects on dyskinesia, PLBs and parkinsonism were determined. The addition of trazodone 10 mg/kg to L-DOPA reduced peak dose dyskinesia by ≈ 39% (P < 0.01) and peak dose PLBs by ≈ 17% (P < 0.01). However, parkinsonian disability was significantly worsened by trazodone 10 mg/kg (P < 0.05) and duration of anti-parkinsonian action was diminished by ≈ 21% (P < 0.05). Our results suggest that trazodone may be effective in alleviating L-DOPA-induced dyskinesia and psychosis in PD, but its deleterious effect on motor function is a concern and may limit its tolerability and usefulness in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset.
- Author
-
Hamadjida, Adjia, Huot, Philippe, Nuara, Stephen G., and Gourdon, Jim C.
- Subjects
- *
MIANSERIN , *PSYCHOSES , *DYSKINESIAS , *PARKINSONIAN disorders , *METHYLPHENYLTETRAHYDROPYRIDINE - Abstract
Background Parkinson's disease (PD) psychosis is a distressing condition that affects up to 60% of patients at the advanced stages of the disease. It significantly impairs patients' and caregivers' quality of life. Current therapeutic options are limited, with only 2 drugs, clozapine and pimavanserin, demonstrating efficacy in randomised controlled trials. These 2 drugs harbour significant affinity for serotonin 2A (5-HT 2A ) receptors, at which they act as antagonists. Mianserin is a non-selective, clinically-available, anti-depressant that blocks 5-HT 2A receptors. Here, we hypothesised that mianserin would effectively alleviate PD psychosis. Methods We tested the anti-psychotic potential of mianserin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset. Six MPTP-lesioned marmosets exhibiting psychosis-like behaviours (PLBs) were administered l -3,4-dihydroxyphenylalanine ( l -DOPA) in combination with mianserin (0.3, 1 and 3 mg/kg) or vehicle, after which the severity of PLBs was rated. We also assessed the effect of mianserin on l -DOPA-induced dyskinesia and parkinsonian disability. Results The addition of mianserin 3 mg/kg to l -DOPA led to a 23% reduction of PLBs ( P < 0.05), when compared to l -DOPA/vehicle. Dyskinesia was reduced, by ≈ 41% ( P < 0.01), when mianserin 3 mg/kg was added to l -DOPA, compared to l -DOPA/vehicle. However, mianserin 3 mg/kg reduced duration of l -DOPA anti-parkinsonian action, by ≈ 18% ( P < 0.05), when compared to l -DOPA/vehicle. Conclusions Our results suggest that mianserin, a clinically-available anti-depressant, may be effective to alleviate both PD psychosis and dyskinesia, but may hinder l -DOPA anti-parkinsonian action, which limits its potential clinical usefulness. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
- Author
-
Huot, Philippe, Johnston, Tom H., Fox, Susan H., Newman-Tancredi, Adrian, and Brotchie, Jonathan M.
- Subjects
- *
DOPA , *PARKINSON'S disease treatment , *DYSKINESIAS , *MOVEMENT disorder treatments , *PHARMACOLOGY , *THERAPEUTICS - Abstract
l -3,4-dihydroxyphenylalanine ( l -DOPA) is the most effective anti-parkinsonian agent available, but upon chronic administration, patients with Parkinson's disease (PD) experience abnormal involuntary movements, dyskinesia. Modulation of serotonin 1A (5-HT 1A ) receptors is regarded as an effective way to alleviate dyskinesia, yet this approach has been marred by a reduction of the therapeutic effectiveness of l -DOPA. We hypothesised that highly-selective 5-HT 1A stimulation might be a way to alleviate dyskinesia without compromising l -DOPA anti-parkinsonian action. F15599 (also known as NLX-101) is a highly-selective 5-HT 1A agonist that displays over 1000 × selectivity over off-target receptors. Seven cynomolgus macaques were administered MPTP and developed severe parkinsonism. Following chronic administration of l -DOPA, they developed severe and reproducible dyskinesia. F15599 (0.003, 0.01, 0.03 and 0.1 mg/kg) or vehicle was administered in combination with l -DOPA and its effect on dyskinesia and l -DOPA anti-parkinsonian was assessed. In combination with l -DOPA, F15599 (0.1 mg/kg) reduced the severity of peak-dose dyskinesia, by ≈45% ( P < 0.001), compared to l -DOPA alone. F15599 (any dose) had no effect on duration of on-time or motor activity counts compared to l -DOPA alone. F15599 at 0.03 and 0.1 mg/kg significantly reduced duration of on-time with disabling dyskinesia (by ≈49% and ≈71%, P < 0.05 and P < 0.001, respectively). These results suggest that F15599, a highly-selective 5-HT 1A receptor agonist, alleviates dyskinesia without exerting a deleterious effect on l -DOPA anti-parkinsonian action. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
- Author
-
Huot, Philippe
- Subjects
- *
DOPA , *DYSKINESIAS , *DOPAMINE , *DRUG efficacy , *DRUG administration - Abstract
l -3,4-Dihydroxyphenylalanine (L-DOPA) is currently the most effective drug available to treat the symptoms of Parkinson's disease (PD). A limitation is that chronic administration of L-DOPA almost invariably, but not universally, leads to the development of abnormal involuntary movements, dyskinesia. Research suggests that striatal dopamine depletion is an important aetiological factor leading to dyskinesia development. However, in studies where L-DOPA was administered to normal animals and human subjects not afflicted by PD, abnormal involuntary movements were sometimes elicited. These studies are reviewed here and their potential significance for the pathophysiology of dyskinesia is discussed. It is concluded that, if striatal dopamine depletion may not be a requisite for the development of dyskinesia, it probably acts as a permissive factor, at least with the doses commonly employed in the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
- Author
-
Huot, Philippe, Johnston, Tom H., Lewis, Katie D., Koprich, James B., Reyes, M. Gabriela, Fox, Susan H., Piggott, Matthew J., and Brotchie, Jonathan M.
- Subjects
- *
DOPAMINE , *SEROTONIN antagonists , *ANTIPARKINSONIAN agents , *DYSKINESIAS , *PSYCHOSES , *MARMOSETS , *DOPA , *THERAPEUTICS - Abstract
Abstract: L-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration is complicated by wearing-off and dyskinesia. UWA-101, a dual, equipotent inhibitor of dopamine (DAT) and serotonin (SERT) transporters, has previously been shown to successfully extend duration of anti-parkinsonian benefit of l-DOPA (ON-time), without exacerbating dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. However, UWA-101 is racemic and it is unclear whether one or both enantiomers contribute to its actions, and whether a better therapeutic effect might be attained by using a single antipode. In the current study, we synthesised the two enantiomers of UWA-101, R-101 (UWA-121) and S-101 (UWA-122), characterised their pharmacological profiles and administered them to MPTP-lesioned marmosets. Parkinsonism, dyskinesia, psychosis-like behaviours and duration of ON-time were evaluated. UWA-121 is a dual DAT > SERT inhibitor, with an approximate 10:1 DAT:SERT affinity ratio (inhibitory constants (Ki) of 307 and 3830 nM, respectively). In combination with l-DOPA, UWA-121 extended duration of ON-time when compared to l-DOPA/vehicle treatment (by 40%, P < 0.01). UWA-121 also extended duration of ON-time without dyskinesia (by 215%, P < 0.05) and ON-time without psychosis-like behaviours when compared to l-DOPA/vehicle treatment (by 345%, P < 0.01). UWA-121 did not worsen the severity of dyskinesia or psychosis-like behaviours (P > 0.05). UWA-122 is a selective SERT inhibitor (Ki 120 nM, Ki at DAT > 50 μM) and, in combination with l-DOPA, had no effect on ON-time, dyskinesia or psychosis-like behaviours (P > 0.05). These data indicate that dual DAT and SERT inhibitors effectively enhance l-DOPA anti-parkinsonian action without worsening dyskinesia and that compounds with such a pharmacological profile represent promising agents against wearing-off in PD. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
21. The serotonergic system in motor and non-motor manifestations of Parkinson's disease.
- Author
-
Huot, Philippe and Fox, Susan
- Subjects
- *
PARKINSON'S disease , *BRAIN diseases , *EXTRAPYRAMIDAL disorders , *SEROTONIN , *DYSKINESIAS , *MENTAL depression , *SEROTONINERGIC mechanisms , *DOPAMINE , *PHYSIOLOGY - Abstract
The understanding of Parkinson's disease (PD) classically revolves around dopamine depletion within the striatum. However, PD is a multi-systemic disease in which extra-dopaminergic systems are affected. The serotonergic (5-HT) system is one of these and has been extensively studied in PD. Although the 5-HT system uses one transporter (SERT) and 14 receptor sub-types, most of the studies in PD have focussed on SERT and serotonergic type 1A and 2A receptors (5-HT and 5-HT). Post-mortem autoradiographic binding studies and in vivo imaging studies have suggested an involvement of the 5-HT system in PD-related anxiety, depression, psychosis and L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Pre-clinical and clinical pharmacological studies have shown that SERT blockade might effectively alleviate depression and dyskinesia and, more recently, might exert disease-modifying effects. Enhancing the physiological activity of 5-HT receptors with 5-HT agonists might alleviate anxiety, dyskinesia and tremor, although a deleterious effect on the anti-parkinsonian efficacy of L-DOPA may ultimately limit the use of this class of compounds. Enhanced 5-HT-mediated neurotransmission has been associated with depression, dyskinesia, psychosis and tremor. The current article critically reviews studies assessing the SERT, as well as 5-HT and 5-HT receptors in idiopathic PD and animal models of PD, and discusses unmet challenges to effectively treat manifestations of PD using SERT antagonists, 5-HT agonists and 5-HT antagonists. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque.
- Author
-
Johnston, Tom H., Huot, Philippe, Fox, Susan H., Koprich, James B., Szeliga, Kendall T., James, John W., Graef, John D., Letchworth, Sharon R., Jordan, Kristen G., Hill, Michael P., and Brotchie, Jonathan M.
- Subjects
- *
NICOTINIC acetylcholine receptors , *DOPA , *DYSKINESIAS , *METHYLPHENYLTETRAHYDROPYRIDINE , *PARKINSON'S disease treatment , *ANTIPARKINSONIAN agents - Abstract
Abstract: Long-term l-DOPA treatment for Parkinson's disease (PD) is limited by motor complications, particularly l-DOPA-induced dyskinesia (LID). A therapy with the ability to ameliorate LID without reducing anti-parkinsonian benefit would be of great value. We assessed the ability of TC-8831, an agonist at nicotinic acetylcholine receptors (nAChR) containing α6β2/α4β2 subunit combinations, to provide such benefits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP) lesioned macaques with established LID. Animals were treated orally for consecutive 14-day periods with twice-daily vehicle (weeks 1–2) or TC-8831 (0.03, 0.1 or 0.3 mg/kg, weeks 3–8). l-DOPA was also administered, once-daily, (weeks 1–12, median-dose 30 mg/kg, p.o.). For the following two-weeks (weeks 9–10), TC-8831 was washed out, while once-daily l-DOPA treatment was maintained. The effects of once-daily amantadine (3 mg/kg, p.o.) were then assessed over weeks 11–12. LID, parkinsonism, duration and quality of ON-time were assessed weekly by a neurologist blinded to treatment. TC-8831 reduced the duration of ‘bad’ ON-time (ON-time with disabling dyskinesia) by up to 62% and decreased LID severity (median score 18 cf. 34 (vehicle), 0.1 mg/kg, 1–3 h period). TC-8831 also significantly reduced choreiform and dystonic dyskinesia (median scores 6 and 31 cf. 19 and 31 respectively (vehicle), both 0.03 mg/kg, 1–3 h). At no time did TC-8831 treatment result in a reduction in anti-parkinsonian benefit of l-DOPA. By comparison, amantadine also significantly reduced dyskinesia and decreased ‘bad’ ON-time (up to 61%) but at the expense of total ON-time (reduced by up to 23%). TC-8831 displayed robust anti-dyskinetic actions and improved the quality of ON-time evoked by l-DOPA without any reduction in anti-parkinsonian benefit. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
23. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
- Author
-
Koprich, James B., Huot, Philippe, Fox, Susan H., Jarvie, Keith, Lang, Anthony E., Seeman, Philip, and Brotchie, Jonathan M.
- Subjects
- *
DYSKINESIAS , *DOPA , *PSYCHOSES , *PARKINSON'S disease treatment , *MACAQUES , *HALOPERIDOL - Abstract
Abstract: 3,4-Dihydroxyphenylalanine (L-DOPA) treatment of Parkinson''s disease (PD) is compromised by motor side effects, such as dyskinesia and non-motor problems, including psychosis. Because of the marked reduction in brain dopamine in PD and the resultant dopamine D2 receptor supersensitivity, it is impossible to use standard potent dopamine D2 receptor antagonists such as haloperidol to alleviate side effects without compromising the anti-parkinsonian benefits of L-DOPA. Haloperidol antagonizes D2 receptors with high affinity and slowly dissociates from D2 receptors (50% dissociation at 38min). We hypothesized that a rapidly dissociating D2 antagonist might allow some functional dopaminergic transmission and thus have a profile, with respect to reduction of dyskinesia and anti-parkinsonian effects, that was more useful therapeutically. The present study tested the principle of using a fast-off-D2 drug, CLR151 (50% dissociation at 23s) to modify L-DOPA actions in cynomolgus macaques with MPTP-parkinsonism. CLR151 (100mg/kg p.o.) reduced L-DOPA-induced dyskinesia and activity in the parkinsonian macaque by 86% and 52% respectively during peak action. CLR151 (100mg/kg) also reduced psychosis-like behaviour (i.e. reduced apparent visual hallucinations by 78%). Nevertheless, this dose of CLR151 significantly reduced the duration of anti-parkinsonian action of L-DOPA, ON-time (by 90%), and increased parkinsonian disability (by 57%). These data suggest that fast-off-D2 dopamine receptor antagonists, with D2-off-rate values close to those for CLR151, are unlikely to be useful in the treatment of dyskinesia and psychosis in PD. However, fast-off-D2 drugs could provide benefit if new congeners would have an even faster dissociation rate. Such drugs are now becoming available. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
24. Effect of the mGlu2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset.
- Author
-
Kang, Woojin, Frouni, Imane, Kwan, Cynthia, Bédard, Dominique, Nuara, Stephen G., Hamadjida, Adjia, Gourdon, Jim C., and Huot, Philippe
- Subjects
- *
DOPA , *MARMOSETS , *ALLOSTERIC regulation , *PARKINSONIAN disorders , *DYSKINESIAS - Abstract
Activation of metabotropic glutamate 2 (mGlu2) receptors is a potential novel therapeutic approach for the treatment of parkinsonism. Thus, when administered as monotherapy or as adjunct to a low dose of L‐3,4‐dihydroxyphenylalanine (L‐DOPA), the mGlu2 positive allosteric modulator (PAM) LY‐487,379 alleviated parkinsonism in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primates. Here, we sought to investigate the effect of biphenyl‐indanone A (BINA), a highly selective mGlu2 PAM whose chemical scaffold is unrelated to LY‐487,379, to determine if a structurally different mGlu2 PAM would also confer anti‐parkinsonian benefit. In monotherapy experiments, MPTP‐lesioned marmosets were injected with either vehicle, L‐DOPA/benserazide (15/3.75 mg/kg, positive control) or BINA (0.1, 1, 10 mg/kg). In adjunct to a low L‐DOPA dose experiments, MPTP‐lesioned marmosets were injected with L‐DOPA/benserazide (7.5/1.875 mg/kg) in combination with vehicle or BINA (0.1, 1, 10 mg/kg). Parkinsonism, dyskinesia and psychosis‐like behaviours (PLBs) were then quantified. When administered alone, BINA 1 and 10 mg/kg decreased parkinsonism severity by ~22% (
p < 0.01) and ~47% (p < 0.001), when compared with vehicle, which was comparable with the global effect of a high L‐DOPA dose. When administered in combination with a low L‐DOPA dose, BINA 1 and 10 mg/kg decreased global parkinsonism by ~38% (p < 0.001) and ~53% (p < 0.001). BINA 10 mg/kg decreased global dyskinesia by ~94% (p < 0.01) and global PLBs by ~92% (p < 0.01). Our results provide additional evidence that mGlu2 positive allosteric modulation elicits anti‐parkinsonian effects. That this benefit is not related to a particular chemical scaffold suggests that it may be a class effect rather than the effect of a specific molecule. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
25. Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain.
- Author
-
Kwan, Cynthia, Lévesque, Catherine, Bédard, Dominique, Frouni, Imane, Yesuf, Jemal M, Hamadjida, Adjia, Lévesque, Daniel, Clarke, Paul BS, and Huot, Philippe
- Subjects
- *
SEROTONIN receptors , *PARKINSON'S disease , *SUBTHALAMIC nucleus , *BASAL ganglia , *DYSKINESIAS - Abstract
• Mechanism underlying anti-dyskinetic efficacy of 5-HT 3 receptor antagonists is unclear. • Dyskinetic hemi-parkinsonian rats showed increased 5-HT 3 levels in the STN, EP and thalamus. • Dyskinesia severity negatively correlated with 5-HT 3 levels in the striatum and STN. • Changes in 5-HT 3 levels in the basal ganglia may modulate l -DOPA induced dyskinesia. L-3,4-dihydroxyphenylalanine (l -DOPA) is the mainstay treatment for Parkinson's disease, but its effectiveness during early disease is marred by the eventual development of l -DOPA induced dyskinesia. In hemi-parkinsonian rats, the serotonin type 3 (5-HT 3) antagonists ondansetron and granisetron alleviated dyskinesia induced by l -DOPA without impeding its anti-parkinsonian action; in parkinsonian marmosets, ondansetron alleviated dyskinesia and enhanced l -DOPA anti-parkinsonian action. Here, we sought to gain insight into the mechanisms governing the anti-dyskinetic action of 5-HT 3 antagonists and measured 5-HT 3 receptor levels across different brain, using [3H]GR65630 autoradiographic binding. Brain sections were chosen from 6-hydroxydopamine (6-OHDA)-lesioned rats exhibiting abnormal involuntary movements (AIMs), as well as l -DOPA-naïve 6−OHDA and sham-lesioned animals. [3H]GR65630 binding increased in the ipsilateral subthalamic nucleus of 6-OHDA-lesioned rats with mild and severe AIMs, (3-fold changes, P < 0.001). [3H]GR65630 binding also increased in the ipsilateral entopeduncular nucleus and thalamus of 6-OHDA-lesioned rats with severe AIMs (75 % and 88 %, P < 0.05). AIMs scores negatively correlated with [3H]GR65630 binding in the ipsilateral dorsolateral striatum and contralateral subthalamic nucleus (P < 0.05). These results suggest that alterations in 5-HT 3 mediated neurotransmission may contribute to the pathophysiology of l -DOPA induced dyskinesia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset.
- Author
-
Hamadjida, Adjia, Nuara, Stephen G., Bédard, Dominique, Gaudette, Fleur, Beaudry, Francis, Gourdon, Jim C., and Huot, Philippe
- Subjects
- *
PARKINSON'S disease , *DYSKINESIAS , *PSYCHOSES , *PHARMACOKINETICS , *SEROTONIN agonists , *DOPA - Abstract
Blockade of serotonin 2A (5-HT 2A ) receptors is regarded as an anti-dyskinetic and anti-psychotic strategy in Parkinson's disease (PD). However, the 5-HT 2A antagonists tested so far exhibited affinity for other receptors, which might have played a role in their action. EMD-281,014 is the most selective 5-HT 2A antagonist available, with approximately 2,000-fold selectivity over serotonin 2C (5-HT 2C ) receptors. EMD-281,014 was previously tested in the clinic and has high translational potential. In the present study, we assessed the effect of EMD-281,014 on dyskinesia and psychosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset. We first determined the pharmacokinetic profile of EMD-281,014 in the marmoset, after which doses leading to clinically-relevant plasma levels (0.01, 0.03 and 0.1 mg/kg) or vehicle were administered to MPTP-lesioned marmosets, in combination with L-3,4-dihydroxyphenylalanine ( l -DOPA). The effects of EMD-281,014 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism were then evaluated. When added to l -DOPA, EMD-281,014 (0.03 and 0.1 mg/kg) reduced peak dose dyskinesia, by 41.8% and 54.5% ( P < 0.05 and P < 0.001), when compared to l -DOPA/vehicle. EMD-281,014 (0.03 and 0.1 mg/kg) also significantly reduced the severity of peak dose PLBs, by 42.5% and 45.9% ( P < 0.05 and P < 0.001), when compared to vehicle. The anti-dyskinetic and anti-psychotic effects of EMD-281,014 were achieved without interfering with l -DOPA anti-parkinsonian action. Our results suggest that highly-selective 5-HT 2A receptor blockade with EMD-281,014 is an effective way to alleviate both dyskinesia and psychosis in PD, without adversely affecting parkinsonian disability. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
- Author
-
Frouni, Imane, Kang, Woojin, Bédard, Dominique, Belliveau, Sébastien, Kwan, Cynthia, Hadj-Youssef, Shadi, Bourgeois-Cayer, Élodie, Ohlund, Leanne, Sleno, Lekha, Hamadjida, Adjia, and Huot, Philippe
- Subjects
- *
GLYCINE agents , *DYSKINESIAS , *PARKINSONIAN disorders , *DOPA , *PARKINSON'S disease , *RATS - Abstract
Dyskinesia remains an unmet need in Parkinson's disease (PD). We have previously demonstrated that glycine transporter 1 (GlyT1) inhibition with ALX-5407 reduces dyskinesia and slightly improves parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Here, we sought to determine the effect of bitopertin, a clinically-tested GlyT1 inhibitor, on parkinsonism and dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat. To do so, we assessed the effect of bitopertin on parkinsonism as monotherapy and as adjunct to a low dose of L-3,4-dihydroxyphenylalanine (L-DOPA). We then assessed the efficacy of bitopertin on dyskinesia in the context of acute challenge and chronic administration studies. Lastly, we evaluated whether de novo treatment with bitopertin, started concurrently with L-DOPA, would diminish the development of dyskinesia. We discovered that bitopertin (0.3 mg/kg), when administered alone, reduced the severity of parkinsonism by 35% (P < 0.01). As adjunct to a low dose of L-DOPA, bitopertin (3 mg/kg) enhanced the anti-parkinsonian effect of L-DOPA by 36% (P < 0.05). Moreover, the acute addition of bitopertin (0.03 mg/kg) to L-DOPA reduced dyskinesia by 27% (P < 0.001), and there was no tolerance to the anti-dyskinetic benefit after 4 weeks of daily administration. Lastly, bitopertin (0.03 mg/kg) started concurrently with L-DOPA, also attenuated the development of dyskinesia, by 33% (P < 0.01), when compared to L-DOPA alone. Our results suggest that GlyT1 inhibition may simultaneously reduce parkinsonism and L-DOPA-induced dyskinesia and represents a novel approach to treat, possibly prevent, motor complications in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
- Author
-
Frouni, Imane, Belliveau, Sébastien, Maddaford, Shawn, Nuara, Stephen G., Gourdon, Jim C., and Huot, Philippe
- Subjects
- *
METHYL aspartate , *GLYCINE agents , *DYSKINESIAS , *MARMOSETS , *CALLITHRIX jacchus , *DOPA , *PARKINSON'S disease , *GLYCINE receptors - Abstract
Dyskinesia and psychosis are complications encountered in advanced Parkinson's disease (PD) following long-term therapy with L-3,4-dihydroxyphenylalanine (L-DOPA). Disturbances in the glutamatergic system have been associated with both dyskinesia and psychosis, making glutamatergic modulation a potential therapeutic approach for these. Treatments thus far have sought to dampen glutamatergic transmission, for example through blockade of N -methyl-D-aspartate (NMDA) receptors or modulation of metabotropic glutamate receptors 5. In contrast, activation of the glycine-binding site on NMDA receptors is required for their physiological response. Here, we investigated whether indirectly enhancing glutamatergic transmission through inhibition of glycine re-uptake would be efficacious in diminishing both dyskinesia and psychosis-like behaviours (PLBs) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset. Six marmosets were rendered parkinsonian by MPTP injection. Following repeated administration of L-DOPA to induce dyskinesia and PLBs, they underwent acute challenges of the glycine transporter 1 (GlyT 1) inhibitor ALX-5407 (0.01, 0.1 and 1 mg/kg) or vehicle, in combination with L-DOPA, after which the severity of dyskinesia, PLBs and parkinsonian disability was evaluated. In combination with L-DOPA, ALX-5407 0.1 and 1 mg/kg significantly reduced the severity of dyskinesia, by 51% and 41% (both P < 0.001), when compared to vehicle. ALX-5407 0.01, 0.1 and 1 mg/kg also decreased the severity of global PLBs, by 25%, 51% and 38% (all P < 0.001), when compared to vehicle. The benefits on dyskinesia and PLBs were achieved without compromising the therapeutic effect of L-DOPA on parkinsonism. Our results suggest that GlyT 1 inhibition may be a novel strategy to attenuate dyskinesia and PLBs in PD, without interfering with L-DOPA anti-parkinsonian action. Inhibition of glycine transporter 1 reduces the expression of established dyskinesia and psychosis in MPTP-lesioned marmosets. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease.
- Author
-
Kwan, Cynthia, Frouni, Imane, Nuara, Stephen G., Belliveau, Sébastien, Kang, Woojin, Hamadjida, Adjia, Bédard, Dominique, Beaudry, Francis, Panisset, Michel, Gourdon, Jim C., and Huot, Philippe
- Subjects
- *
PARKINSON'S disease , *DYSKINESIAS , *SEROTONIN receptors , *PSYCHOSES , *SYMPTOMS , *METHYL aspartate , *TRYPTOPHAN - Abstract
Antagonising the serotonin 2A (5-HT 2A) receptor is an efficacious way to alleviate dyskinesia and psychosis in Parkinson's disease (PD). However, previous research indicates that there might be a limit to the effects conferred by this approach. 5-HT 2A receptors were shown to form hetero-dimers with metabotropic glutamate 2 (mGlu 2) receptors, in which 5-HT 2A blockade and mGlu 2 activation elicit equivalent effects at the downstream signalling level. We have previously shown that mGlu 2 activation reduces both dyskinesia and psychosis-like behaviours (PLBs) induced by L-3,4-dihydroxyphenylalanine (l -DOPA), in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate. Here, we hypothesised that concurrent 5-HT 2A antagonism and mGlu 2 activation would provide greater anti-dyskinetic and anti-psychotic benefits than either approach alone. We conducted 3 series of experiments in the MPTP-lesioned marmoset. In the first series of experiments, the mGlu 2 positive allosteric modulator LY-487,379 and the 5-HT 2A antagonist EMD-281,014, either alone or in combination, were added to l -DOPA. In the second series of experiments, the mGlu 2/3 orthosteric agonist LY-354,740 and EMD-281,014, either alone or in combination, were added to l -DOPA. In the last series of experiments, we investigated whether mGlu 2 blockade would diminish the effects of antagonising 5-HT 2A receptors. To this end, the mGlu 2/3 orthosteric antagonist LY-341,495 and EMD-281,014, either alone or in combination, were added to l -DOPA. We found that the anti-dyskinetic effect of the combination LY-487,379/EMD-281,014 was greater than the ones conferred by LY-487,379 (by 35%, P < 0.05) and EMD-281,014 (by 38%, P < 0.01). The anti-dyskinetic and anti-psychotic effects of the combination LY-354,740/EMD-281,014 were also greater than the ones conferred by LY-354,740 (by 57% for dyskinesia and 54% for PLBs, both P < 0.001) and EMD-281,014 (by 61% for dyskinesia and 53% for PLBs, both P < 0.001). The anti-parkinsonian action of l -DOPA was maintained with all treatments. Lastly, the addition of LY-341,495 abolished the therapeutic effects of EMD-281,014 on dyskinesia and PLBs. Our results suggest that mGlu 2 activation may enhance the anti-dyskinetic and anti-psychotic effects of 5-HT 2A blockade and could provide relief to PD patients with dyskinesia and psychotic symptoms beyond what can be achieved with current therapies. • An additive anti-dyskinetic effect is achieved upon concurrent mGlu 2 activation and 5-HT 2A blockade. • An additive anti-psychotic effect is achieved upon concurrent mGlu 2 activation and 5-HT 2A blockade. • Combined mGlu 2 activation and 5-HT 2A blockade does not hamper l -DOPA anti-parkinsonian action. • mGlu 2 blockade hinders the anti-dyskinetic and anti-psychotic effects of 5-HT 2A antagonism. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset.
- Author
-
Kwan, Cynthia, Nuara, Stephen G., Bédard, Dominique, Gaudette, Fleur, Gourdon, Jim C., Beaudry, Francis, and Huot, Philippe
- Subjects
- *
SEROTONIN receptors , *DYSKINESIAS , *MARMOSETS , *ONDANSETRON , *PARKINSON'S disease - Abstract
In Parkinson's disease (PD), management of L-3,4-dihydroxyphenylalanine (l -DOPA)-related complications, such as l -DOPA induced dyskinesia and psychosis, remains inadequate, which poses a significant burden on the quality of life of patients. We have shown, in the hemi-parkinsonian rat model of PD, that the selective serotonin type 3 (5-HT 3) receptor antagonists ondansetron and granisetron decreased the severity of established dyskinesia, and ondansetron even attenuated the development of dyskinesia. Here, we seek to confirm these favourable data on dyskinesia and to explore the effect of ondansetron on the severity of psychosis-like behaviours (PLBs) in the gold standard model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned non-human primate. We first determined the pharmacokinetic profile of ondansetron in the marmoset. Subsequently, six MPTP-lesioned marmosets were administered l -DOPA chronically until they exhibited stable and reproducible dyskinesia and PLBs upon each administration of l -DOPA. On behavioural assessment days, ondansetron (0.01, 0.1 and 1 mg/kg) or vehicle was administered in conjunction with l -DOPA, and the severity of dyskinesia, PLBs and parkinsonism was evaluated. Ondansetron 0.1 mg/kg alleviated global dyskinesia severity by 73% (P < 0.0001) and decreased duration of on-time with disabling dyskinesia by 88% (P = 0.0491). Ondansetron 0.1 mg/kg reduced the severity of global PLBs by 80% (P < 0.0001) and suppressed on-time with disabling PLBs (P = 0.0213). Ondansetron enhanced the anti-parkinsonian action of l -DOPA, reducing global parkinsonism by 53% compared to l -DOPA (P = 0.0004). These results suggest that selective blockade of the 5-HT 3 receptor with ondansetron may be an effective approach to alleviate l -DOPA-related complications. • The pharmacokinetic profile of ondansetron was assessed in the marmoset. • 5-HT 3 blockade alleviates l -DOPA-induced dyskinesia in the MPTP-lesioned marmoset. • 5-HT 3 blockade alleviates psychosis-like behaviours in the MPTP-lesioned marmoset. • 5-HT 3 blockade enhances anti-parkinsonian benefit conferred by l -DOPA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
- Author
-
Sid-Otmane, Lamia, Hamadjida, Adjia, Nuara, Stephen G., Bédard, Dominique, Gaudette, Fleur, Gourdon, Jim C., Michaud, Véronique, Beaudry, Francis, Panisset, Michel, and Huot, Philippe
- Subjects
- *
ALLOSTERIC regulation , *GLUTAMATE receptors , *DYSKINESIAS , *MARMOSETS , *METHYL aspartate , *CALLITHRIX jacchus - Abstract
Psychosis and dyskinesia significantly diminish the quality of life of patients with advanced Parkinson's disease (PD). Available treatment options are unfortunately few and their use is limited by adverse effects. We have recently shown that activation of metabotropic glutamate 2 and 3 (mGlu2/3) receptors produced significant relief of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in experimental models of PD. Here, using the highly-selective mGlu2 positive allosteric modulator (PAM) LY-487,379, we seek to determine the contribution of selective mGlu2 activation on both L-DOPA-induced PLBs and dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate. We first determined the pharmacokinetic (PK) profile of LY-487,379 in the common marmoset, following which we administered it (0.1, 1 and 10 mg/kg) or its vehicle to 6 MPTP-lesioned marmosets previously exposed to L-DOPA to elicit stable PLBs and dyskinesia. We found that LY-487,379 provided a ≈45% reduction of the global PLBs observed and reduced global dyskinesia score by ≈ 55%. Moreover, LY-487,379 enhanced the anti-parkinsonian effect of L-DOPA, by reducing global parkinsonian score by ≈ 15%. Our data suggest that selective mGlu2 positive allosteric modulation with LY-487,379 may represent a potential therapeutic approach to alleviate both L-DOPA-induced PLBs and dyskinesia in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
- Author
-
Kwan, Cynthia, Frouni, Imane, Bédard, Dominique, Hamadjida, Adjia, and Huot, Philippe
- Subjects
- *
PARKINSON'S disease , *DOPAMINE , *DYSKINESIAS , *DOPA , *RATS - Abstract
L-3,4-dihydroxyphenylalanine (L-DOPA) has been the standard treatment for Parkinson's disease (PD), despite that its chronic use leads to motor fluctuations and dyskinesia in as many as 95% of patients. Previous studies have shown that serotonin type 3 (5-HT 3) receptor blockade reduces dopamine levels within the striatum, suggesting that it could potentially lead to a reduction of dyskinesia. Here, we assessed the effects of ondansetron on L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat. We performed two series of experiments. First, rats exhibiting stable AIMs were administered ondansetron (0.0001, 0.001, 0.01, 0.1 and 1 mg/kg) or vehicle in combination with L-DOPA, following which the effect of ondansetron on AIMs was assessed. In the second series of experiments, following 6-OHDA lesion, rats received daily administration of ondansetron (0.0001, 0.001 mg/kg) or vehicle, started concurrently with the first L-DOPA dose, and treatments were continued for 22 days. After a washout period, an acute L-DOPA challenge was administered and AIMs severity was assessed. The effect of ondansetron on L-DOPA anti-parkinsonian action was also determined. We found that the addition of ondansetron 0.0001 mg/kg to L-DOPA resulted in a significant reduction of AIMs severity (by 31%, P < 0.001), when compared to vehicle. Ondansetron 0.0001 mg/kg, when started concurrently with L-DOPA, also attenuated the development of AIMs, with AIMs being 64% less severe (P < 0.05), when compared to L-DOPA/vehicle. Ondansetron did not impair L-DOPA anti-parkinsonian action. Our results suggest that selective 5-HT 3 blockade is a promising strategy to reduce the severity of L-DOPA-induced dyskinesia and may also attenuate its development. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism.
- Author
-
Frouni, Imane, Hamadjida, Adjia, Kwan, Cynthia, Bédard, Dominique, Nafade, Vaidehi, Gaudette, Fleur, Nuara, Stephen G., Gourdon, Jim C., Beaudry, Francis, and Huot, Philippe
- Subjects
- *
SEROTONIN receptors , *PARKINSON'S disease , *PSYCHOSES , *DYSKINESIAS , *MARMOSETS - Abstract
Selective blockade of serotonin 2A (5-HT 2A) receptors is a promising strategy to reduce L-3,4-dihydroxyphenylalanine (l -DOPA)-induced dyskinesia and has shown efficacy in a Phase III clinical trial for dopaminergic psychosis in Parkinson's disease (PD). However, pre-clinical and clinical evidence suggest that, while this approach may be effective and well tolerated, there might be a ceiling beyond which no further therapeutic benefit might be achieved. There is mounting evidence that 5-HT 2A receptors form a functional hetero-complex with metabotropic glutamate 2 (mGlu 2) receptors, with antagonism of 5-HT 2A receptors and activation of mGlu 2 receptors producing similar effects on the Gi/Gq signalling ratio at the intra-cellular level. Based on this interaction between 5-HT 2A and mGlu 2 receptors, we hypothesised that activation of mGlu 2 receptors would alleviate dyskinesia and psychosis in PD. LY-354,740 is a selective mGlu 2/3 orthosteric agonist that was previously tested in the clinic. In experiments conducted in the 6-hydroxydopamine (6-OHDA)-lesioned rat and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset, we found that mGlu 2/3 activation with LY-354,740 significantly reduced the expression of dyskinesia and psychosis-like behaviours, while simultaneously enhancing l -DOPA therapeutic benefit. Moreover, mGlu 2/3 activation with LY-354,740 attenuated the development of dyskinesia. These data indicate that activation of mGlu 2/3 receptors is a therapeutic strategy that may provide relief for both motor and-non-motor treatment-related complications in PD. • We have determined the pharmacokinetic profile of LY-354,740 in the marmoset. • LY-354,740 reduces l -DOPA-induced dyskinesia in the 6-OHDA-lesioned rat. • LY-354,740 reduces l -DOPA-induced dyskinesia in the MPTP-lesioned marmoset. • LY-354,740 reduces l -DOPA-induced psychosis in the MPTP-lesioned marmoset. • LY-354,740 does not interfere with the anti-parkinsonian action of l -DOPA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.